SOLVE-TAVI试验5年结果:TAVR瓣膜类型与麻醉策略的影响
SOLVE-TAVI随机试验将447例中高危重度症状性主动脉瓣狭窄患者按2×2析因设计分配至自膨胀瓣膜或球囊扩张瓣膜,以及清醒镇静或全身麻醉,随访5年。结果显示两组瓣膜在预设复合终点上无显著差异,但自膨胀瓣膜组5年卒中率更低;清醒镇静组5年全因死亡率更低,麻醉策略主要终点无显著差异。
要点
- 自膨胀瓣膜与球囊扩张瓣膜5年复合终点无显著差异。
- 自膨胀瓣膜组5年卒中率显著低于球囊扩张瓣膜组。
- 清醒镇静组5年全因死亡率显著低于全身麻醉组。
核心结论
- 经股动脉TAVR使用自膨胀瓣膜或球囊扩张瓣膜、以及清醒镇静或全身麻醉,5年复合临床终点相似。
- 自膨胀瓣膜组5年卒中率更低,清醒镇静组5年全因死亡率更低。
研究设计与样本
- 随机、多中心、2×2析因、开放标签SOLVE-TAVI试验,纳入447例中高危重度症状性主动脉瓣狭窄患者。
- 患者随机接受自膨胀瓣膜(Evolut R)或球囊扩张瓣膜(SAPIEN 3),并随机接受清醒镇静或全身麻醉,随访5年。
主要发现
- 自膨胀瓣膜组与球囊扩张瓣膜组预设复合终点(全因死亡、卒中、中重度瓣周漏、永久起搏器植入)发生率分别为67.7%与63.4%(HR 0.89;95%CI 0.70-1.13;P=0.34)。
- 5年卒中率自膨胀瓣膜组为2.2%,球囊扩张瓣膜组为9.6%(HR 4.84;95%CI 1.65-14.18;P=0.002)。
- 麻醉策略主要终点(全因死亡、卒中、心肌梗死、急性肾损伤)在清醒镇静组为51.4%,全身麻醉组为61.3%(HR 0.80;95%CI 0.62-1.04;P=0.09)。
- 5年全因死亡率清醒镇静组为41.5%,全身麻醉组为54.3%(HR 0.70;95%CI 0.53-0.94;P=0.02)。
临床怎么用
- 对于中高危重度症状性主动脉瓣狭窄行经股动脉TAVR的患者,选择自膨胀瓣膜或球囊扩张瓣膜均可,但需权衡卒中风险。
- 清醒镇静策略可能与更低的5年全因死亡率相关,在合适患者中可考虑优先选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the randomized SOLVE-TAVI (compariSon of secOnd-generation seLf-expandable vs. balloon-expandable Valves and gEneral vs. local anesthesia in Transcatheter Aortic Valve Implantation) trial comparing newer-generation self-expanding valves (SEV) and balloon-expandable valves (BEV), as well as conscious sedation (CS) and general anesthesia (GA), clinical outcomes were similar both for valve and anesthesia comparison at 30 days and 1 year. Prosthesis durability may affect clinical outcomes during long-term follow-up. Moreover, the impact of the anesthesia strategy on long-term clinical outcomes is unknown so far. OBJECTIVES: The authors sought to compare clinical outcomes during 5-year follow-up in the randomized SOLVE-TAVI trial. METHODS: In the randomized, multicenter, 2 × 2 factorial, open-label SOLVE-TAVI trial, 447 intermediate- to high-risk patients with severe, symptomatic aortic stenosis were randomly assigned to transfemoral transcatheter aortic valve replacement (TAVR) using either SEV (Evolut R, Medtronic) or BEV (SAPIEN 3, Edwards Lifesciences) and also to CS vs GA. Patients were followed-up for 5 years. RESULTS: During 5 years of follow-up, the combined predefined endpoint of all-cause mortality, stroke, moderate or severe paravalvular leakage, and permanent pacemaker implantation was similar in the SEV and BEV groups (67.7% vs 63.4%; HR: 0.89; 95% CI: 0.70-1.13; P = 0.34). Stroke rates at 5 years were lower in the SEV group (2.2% vs 9.6%; HR: 4.84; 95% CI: 1.65-14.18; P = 0.002). Regarding the anesthesia comparison, the primary endpoint of all-cause mortality, stroke, myocardial infarction, and acute kidney injury occurred in 51.4% in the CS group and 61.3% in the GA group (HR: 0.80; 95% CI: 0.62-1.04; P = 0.09). All-cause mortality at 5 years was lower for CS (41.5% vs 54.3%; HR: 0.70; 95% CI: 0.53-0.94; P = 0.02). CONCLUSIONS: Transfemoral TAVR using either SEV and BEV as well as CS and GA showed similar clinical outcomes at 5 years using a combined clinical endpoint.
引用
- Feistritzer HJ, Kurz T, Vonthein R, et al. Effect of Valve Type and Anesthesia Strategy for TAVR: 5-Year Results of the SOLVE-TAVI Trial. J Am Coll Cardiol. 2024. PMID: 39503651. doi:10.1016/j.jacc.2024.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。